Dr. Al B. Benson
Claim this profileNorthwestern University
Studies Neuroendocrine Tumors
Studies Adenocarcinoma
10 reported clinical trials
22 drugs studied
Area of expertise
1Neuroendocrine Tumors
Stage IV
Stage III
2Adenocarcinoma
Stage IV
Stage III
BRAF negative
Affiliated Hospitals
Clinical Trials Al B. Benson is currently running
Triapine + Targeted Radiation
for Neuroendocrine Cancer
This phase II trial compares the effect of adding triapine to lutetium Lu 177 dotatate versus lutetium Lu 177 dotatate alone (standard therapy) in shrinking tumors or slowing tumor growth in patients with neuroendocrine tumors that have spread from where they first started (primary site) to other places in the body (metastatic). Triapine may stop the growth of tumor cells by blocking some of the enzymes needed for deoxyribonucleic acid synthesis and cell growth. Lutetium Lu 177 dotatate is a radioactive drug. It binds to a protein called somatostatin receptor, which is found on some neuroendocrine tumor cells. Lutetium Lu 177 dotatate builds up in these cells and gives off radiation that may kill them. It is a type of radioconjugate and a type of somatostatin analog. Giving triapine in combination with lutetium Lu 177 dotatate may be more effective at shrinking tumors or slowing tumor growth in patients with metastatic neuroendocrine tumors than the standard therapy of lutetium Lu 177 dotatate alone.
Recruiting1 award Phase 2
Preoperative Chemotherapy + Surgery
for Sarcoma
This is a multicenter, randomized, open label phase lll trial to assess whether preoperative chemotherapy, as an adjunct to curative-intent surgery, improves the prognosis of high risk DDLPS (dedifferentiated Liposarcoma) and LMS (Leiomyosarcoma) patients as measured by disease free survival. After confirmation of eligibility criteria, patients will be randomized to either the standard arm or experimental arm.
Recruiting2 awards Phase 35 criteria
More about Al B. Benson
Clinical Trial Related1 year of experience running clinical trials · Led 10 trials as a Principal Investigator · 6 Active Clinical TrialsTreatments Al B. Benson has experience with
- Lutetium Lu 177 Dotatate
- Oxaliplatin
- Trastuzumab
- Pertuzumab
- Cetuximab
- Irinotecan Hydrochloride
Breakdown of trials Al B. Benson has run
Neuroendocrine Tumors
Adenocarcinoma
Cancer
Rectal Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Al B. Benson specialize in?
Al B. Benson focuses on Neuroendocrine Tumors and Adenocarcinoma. In particular, much of their work with Neuroendocrine Tumors has involved Stage IV patients, or patients who are Stage III.
Is Al B. Benson currently recruiting for clinical trials?
Yes, Al B. Benson is currently recruiting for 6 clinical trials in Chicago Illinois. If you're interested in participating, you should apply.
Are there any treatments that Al B. Benson has studied deeply?
Yes, Al B. Benson has studied treatments such as Lutetium Lu 177 Dotatate, Oxaliplatin, Trastuzumab.
What is the best way to schedule an appointment with Al B. Benson?
Apply for one of the trials that Al B. Benson is conducting.
What is the office address of Al B. Benson?
The office of Al B. Benson is located at: Northwestern University, Chicago, Illinois 60611 United States. This is the address for their practice at the Northwestern University.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.